Joel Werier1, Xiaomei Yao2, Jean-Michel Caudrelier1, Gina Di Primio3, Michelle Ghert4, Abha A Gupta5, Rita Kandel6, Shailendra Verma1. 1. The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada. 2. Cancer Care Ontario, Program in Evidence-Based Care, McMaster University, Hamilton, Ontario, Canada. Electronic address: yaoxia@mcmaster.ca. 3. St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada. 4. Juravinski Cancer Centre, Hamilton, Ontario, Canada. 5. The Hospital for Sick Children, Toronto, Ontario, Canada. 6. Mount Sinai Hospital, Toronto, Ontario, Canada.
Abstract
OBJECTIVE: To perform a systematic review to investigate the optimal treatment strategy among the options of surgery alone, radiotherapy (RT) alone, and the combination of RT plus surgery in the management of localized Ewing's sarcoma of bone following neo-adjuvant chemotherapy. METHODS: MEDLINE and EMBASE (1999 to February 2015), the Cochrane Library, and relevant conferences were searched. RESULTS: Two systematic reviews and eight full texts met the pre-planned study selection criteria. When RT was compared with surgery, a meta-analysis combining two papers showed that surgery resulted in a higher event-free survival (EFS) than RT in any location (HR = 1.50, 95% CI 1.12-2.00; p = 0.007). However another paper did not find a statistically significant difference in patients with pelvic disease, and no papers identified a significant difference in overall survival. When surgery plus RT was compared with surgery alone, a meta-analysis did not demonstrate a statistically significant difference for EFS between the two groups (HR = 1.21, 95% CI 0.90-1.63). Both surgical morbidities and radiation toxicities were reported. CONCLUSIONS: The existing evidence is based on very low aggregate quality as assessed by the GRADE approach. In patients with localized Ewing's sarcoma, either surgery alone (if complete surgical excision with clear margin can be achieved) or RT alone may be a reasonable treatment option. The optimal local treatment for an individual patient should be decided through consideration of patient characteristics, the potential benefit and harm of the treatment options, and patient preference. Crown
OBJECTIVE: To perform a systematic review to investigate the optimal treatment strategy among the options of surgery alone, radiotherapy (RT) alone, and the combination of RT plus surgery in the management of localized Ewing's sarcoma of bone following neo-adjuvant chemotherapy. METHODS: MEDLINE and EMBASE (1999 to February 2015), the Cochrane Library, and relevant conferences were searched. RESULTS: Two systematic reviews and eight full texts met the pre-planned study selection criteria. When RT was compared with surgery, a meta-analysis combining two papers showed that surgery resulted in a higher event-free survival (EFS) than RT in any location (HR = 1.50, 95% CI 1.12-2.00; p = 0.007). However another paper did not find a statistically significant difference in patients with pelvic disease, and no papers identified a significant difference in overall survival. When surgery plus RT was compared with surgery alone, a meta-analysis did not demonstrate a statistically significant difference for EFS between the two groups (HR = 1.21, 95% CI 0.90-1.63). Both surgical morbidities and radiation toxicities were reported. CONCLUSIONS: The existing evidence is based on very low aggregate quality as assessed by the GRADE approach. In patients with localized Ewing's sarcoma, either surgery alone (if complete surgical excision with clear margin can be achieved) or RT alone may be a reasonable treatment option. The optimal local treatment for an individual patient should be decided through consideration of patient characteristics, the potential benefit and harm of the treatment options, and patient preference. Crown
Authors: C Theil; J Röder; G Gosheger; N Deventer; R Dieckmann; D Schorn; J Hardes; D Andreou Journal: Clin Orthop Relat Res Date: 2019-12 Impact factor: 4.176
Authors: Simone de Campos Vieira Abib; Chan Hon Chui; Sharon Cox; Abdelhafeez H Abdelhafeez; Israel Fernandez-Pineda; Ahmed Elgendy; Jonathan Karpelowsky; Pablo Lobos; Marc Wijnen; Jörg Fuchs; Andrea Hayes; Justin T Gerstle Journal: Ecancermedicalscience Date: 2022-02-17
Authors: S Peter Wu; Benjamin T Cooper; Fang Bu; Christopher J Bowman; J Keith Killian; Jonathan Serrano; Shiyang Wang; Twana M Jackson; Daniel Gorovets; Neerav Shukla; Paul A Meyers; David J Pisapia; Richard Gorlick; Marc Ladanyi; Kristen Thomas; Matija Snuderl; Matthias A Karajannis Journal: JCO Precis Oncol Date: 2017-10-06
Authors: Dimosthenis Andreou; Andreas Ranft; Georg Gosheger; Beate Timmermann; Ruth Ladenstein; Wolfgang Hartmann; Sebastian Bauer; Daniel Baumhoer; Henk van den Berg; P D Sander Dijkstra; Hans Roland Dürr; Hans Gelderblom; Jendrik Hardes; Lars Hjorth; Justus Kreyer; Jarmila Kruseova; Andreas Leithner; Sergiu Scobioala; Arne Streitbürger; Per-Ulf Tunn; Eva Wardelmann; Reinhard Windhager; Heribert Jürgens; Uta Dirksen Journal: Clin Orthop Relat Res Date: 2020-02 Impact factor: 4.755
Authors: Jeremy Whelan; Allan Hackshaw; Anne McTiernan; Robert Grimer; David Spooner; Jessica Bate; Andreas Ranft; Michael Paulussen; Herbert Juergens; Alan Craft; Ian Lewis Journal: Clin Sarcoma Res Date: 2018-03-30